Document is current
Any future updates will be listed below
-
Authors
Ostrominski, John W. https://orcid.org/0000-0002-2866-9414
Aroda, Vanita R. https://orcid.org/0000-0002-7706-4585
Braae, Uffe C. https://orcid.org/0000-0002-2743-4584
Kruse, Christian https://orcid.org/0000-0001-5590-2245
Mandavya, Kabirdev https://orcid.org/0000-0003-3046-4503
Buse, John B. https://orcid.org/0000-0002-9723-3876
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 28 February 2025
Accepted: 25 April 2025
First Online: 22 May 2025
Declarations
:
: John W. Ostrominski has received research support from the National Institutes of Health (5T32HL007604-39). Vanita R. Aroda has received research support from Amgen, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Corcept Therapeutics, Eli Lilly, Fractyl Health, Inc., Novo Nordisk A/S, Pfizer, Rhythm, and Servier, and consulting fees from Fractyl, Mediflix, Novo Nordisk, Pfizer, and Sanofi. Uffe C. Braae, Christian Kruse, and Kabirdev Mandavya are employees and shareholders of Novo Nordisk A/S. John B. Buse has received research support from Bayer, Boehringer Ingelheim, Carmot Therapeutics, Corcept Therapeutics, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics; consulting fees from Alkahest, Altimmune, Anji Pharmaceuticals, Aqua Medical, AstraZeneca, Boehringer Ingelheim, CeQur, Corcept Therapeutics, Eli Lilly, Embecta, GentiBio, Glyscend, Insulet, Mediflix, Medscape, Medtronic, Mellitus Health, Metsera, Moderna, Novo Nordisk, Pendulum Therapeutics, Praetego, ReachMD, Stability Health, Tandem Health, Terns Pharmaceuticals, and Vertex; and stock options from Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego, and Stability Health.
: This study was a retrospective analysis of secondary de-identified data; therefore, ethical approval was not required.
